Key Highlights

  • Net loss for the third quarter ended September 30, 2026 was USD 37.8 million, or USD 1.81 per share, compared with USD 23.3 million, or USD 1.90 per share, in the third quarter of 2025.
  • Research and development expense rose 64% to USD 34.2 million, and costs for sutantatug envedotin grew to USD 26.8 million from USD 9.6 million, including a USD 15.0 million CSPC development milestone achieved in the third quarter.
  • General and administrative expense increased 29% to USD 4.6 million, mainly on higher compensation tied to headcount, while total other income was USD 1.1 million, comparable with the prior year.
  • Cash, cash equivalents and investments were about USD 115.3 million at September 30, 2026, which management expects to meet operating needs for at least twelve months from the filing.

A USD 15.0 Million Milestone Inflates Research Spending

Corbus Pharmaceuticals (NASDAQ:CRBP) filed its Quarterly Report on November 10, 2026, for the period ended September 30, 2026. The clinical-stage company has no Revenue and develops oncology and obesity drugs. Operating expenses were USD 38.8 million against USD 24.4 million a year earlier, and the net loss widened by USD 14.4 million. Research and Development rose USD 13.4 million to USD 34.2 million. Sutantatug envedotin, a Nectin-4 targeting antibody drug conjugate, accounted for USD 17.2 million of the increase, mainly from the USD 15.0 million milestone owed to CSPC and the start of enrollment in the TEMPO-1 study. Program-specific costs overall rose to USD 31.3 million from USD 18.2 million, while internal personnel costs were about USD 2.5 million.

Obesity Candidate Spending Rises While CRB-601 Winds Down

CRB-913, an oral cannabinoid receptor inverse agonist for obesity, cost USD 4.3 million against USD 3.7 million, as the Phase 1b portion of its study completed participant treatment. Spending on CRB-601 fell to USD 0.1 million from USD 4.8 million because its Phase 1 dose escalation study finished and no more patients were enrolled in 2026. For nine months, the net loss was USD 95.8 million, or USD 4.87 per share, against USD 58.0 million, or USD 4.73. Operating cash outflow for the nine months was USD 76.4 million, versus USD 48.6 million a year earlier.

Twelve Months of Cash and Dependence on New Capital

The company reported an accumulated Deficit of about USD 651.2 million and working Capital of about USD 84.0 million. The management discussion cited total cash, investments and restricted cash of USD 115.7 million, while the Liquidity note cites USD 115.3 million of cash, equivalents and investments, a gap that appears to reflect restricted cash. Of the total, about USD 112.1 million was held in the United States. The filing says the company will depend on raising substantial additional capital before it can become profitable, and that it may never do so. The most recent Equity raise noted was an underwritten public offering completed on November 3, 2025. No guidance or share price reaction was included in the material reviewed.

Where Things Stand

A single USD 15.0 million milestone explains much of the increase, though clinical spending is also rising. Corbus Pharmaceuticals (NASDAQ:CRBP) lost USD 37.8 million in the quarter as development costs for sutantatug envedotin grew with TEMPO-1 enrollment, and obesity work continues. Cash of about USD 115.3 million is described as enough for at least twelve months. Next markers include further CSPC milestone payments, TEMPO-1 progress, CRB-913 development and the timing of the next financing.